29TA Stock Overview
Operates as a pharmaceutical royalty company in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
TherapeuticsMD, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.83 |
| 52 Week High | US$4.08 |
| 52 Week Low | US$1.73 |
| Beta | 1.07 |
| 1 Month Change | -14.49% |
| 3 Month Change | -12.02% |
| 1 Year Change | -53.55% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| 29TA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 5.8% | 6.1% | 1.6% |
| 1Y | -53.6% | -17.5% | 7.3% |
Return vs Industry: 29TA underperformed the German Pharmaceuticals industry which returned -21.6% over the past year.
Return vs Market: 29TA underperformed the German Market which returned 6.5% over the past year.
Price Volatility
| 29TA volatility | |
|---|---|
| 29TA Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.6% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 29TA's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 29TA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 1 | Marlan Walker | www.therapeuticsmd.com |
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.
TherapeuticsMD, Inc. Fundamentals Summary
| 29TA fundamental statistics | |
|---|---|
| Market cap | €21.66m |
| Earnings (TTM) | -€5.71m |
| Revenue (TTM) | €1.10m |
20.1x
P/S Ratio-3.9x
P/E RatioIs 29TA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 29TA income statement (TTM) | |
|---|---|
| Revenue | US$1.20m |
| Cost of Revenue | US$0 |
| Gross Profit | US$1.20m |
| Other Expenses | US$7.40m |
| Earnings | -US$6.20m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.54 |
| Gross Margin | 100.00% |
| Net Profit Margin | -516.93% |
| Debt/Equity Ratio | 0% |
How did 29TA perform over the long term?
See historical performance and comparison